Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment [0.03%]
揭开抗体药物偶联物在癌症治疗中的分子和免疫学驱动因素
Alfred Zippelius,Sara M Tolaney,Paolo Tarantino et al.
Alfred Zippelius et al.
After decades of investment, antibody-drug conjugates (ADCs) are finally demonstrating their potential, marked by a growing number of clinical approvals, applications in earlier lines of treatment and integration into drug combinations, inc...
Tamoxifen takes the wheel [0.03%]
他莫昔芬掌控全局
Daniela Senft
Daniela Senft
Identification, functional insights and therapeutic targeting of EMT tumour states [0.03%]
上皮间质转化肿瘤亚型的鉴定、功能分析及治疗靶向研究
Anqi Dong,Cédric Blanpain
Anqi Dong
Epithelial-to-mesenchymal transition (EMT) is a cellular process during which cells lose their epithelial characteristics and acquire mesenchymal features with enhanced migration capacities. EMT has key roles in different aspects of tumorig...
Unlocking the potential of urine-based liquid biopsy through improved reporting and standardization [0.03%]
通过改进报告和标准化解锁尿液液体活检的潜力
Douglas G Ward,Richard T Bryan,Aadel A Chaudhuri et al.
Douglas G Ward et al.
Implementing practice-changing progress for managing cancer of unknown primary [0.03%]
促进未知原发灶癌症管理的进展措施
F Anthony Greco
F Anthony Greco
Discovering genetic interactions that cause melanoma in a non-model species [0.03%]
在非模式物种中发现导致黑色素瘤的基因互作
Alessandro Lopez-Hernandez,Diego Ortega-Del Vecchyo
Alessandro Lopez-Hernandez
Slaying the pre-TCR beast [0.03%]
击杀前TCR怪兽
Gabrielle Brewer
Gabrielle Brewer
Kilian B Kennel,Florian R Greten
Kilian B Kennel
Colorectal cancer (CRC) progression depends on the close interaction of tumour cells and the tumour microenvironment (TME). Although the TME contributes to poor therapy responses and immune evasion, immune cells within the TME can be therap...
James R Hebert,E Angela Murphy,Mary C Playdon et al.
James R Hebert et al.